Support of the PBM Accountability Study Act (HR 1829)

The HIV+Hepatitis Policy Institute strongly supports The PBM Accountability Study Act (HR 1829), which would require the Government Accountability Office to provide a comprehensive report to Congress on the ways in which PBMs influence the pricing of pharmaceuticals, impede competition, use rebates and also provide recommendations on ways to lower prescription drug costs.

read more

Support of Louisiana SB 94 so that patients can afford their prescription medications

The HIV+HEP Policy Institute is a leading HIV and hepatitis policy organization promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions. We strongly support Senate Bill 94, which would require health insurers and health care service contractors to accept and count payments made on behalf of patients towards deductibles and out‐of‐pocket maximums.

read more

Pin It on Pinterest